Anixa Biosciences, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Anixa Biosciences, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 90% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-175.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 90% of Healthcare companies in United States.
Cash Cushion Ratio
+15%Cash, after subtracting all debt, equals 15% of its market value (net cash).
Higher than 58% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Anixa Biosciences, Inc. made a loss over the last year. Anixa Biosciences, Inc. owes $0.12 for every $1 it owns. Anixa Biosciences, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Oct 2025.
P/E ratio
LossAnixa Biosciences, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.68The share price is 6.68 times Anixa Biosciences, Inc.'s book value per share, higher than 79% of Healthcare companies in United States.
Market cap
$97 MThe total market value of all of Anixa Biosciences, Inc.'s shares at today's price (share price × number of shares), smaller than 66% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$14 MWhat Anixa Biosciences, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Jul 2026).
Book value per share
$0.42Net worth divided by the number of shares. The share price of $2.78 is 6.7 times this, which is the P/B above.
Return on equity (ROE)
-73.2%Anixa Biosciences, Inc. lost 73.2% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
Owes vs Owns
0.12×Anixa Biosciences, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Dividend yield
NoneAnixa Biosciences, Inc. does not currently pay a dividend.
Profit growth
LossAnixa Biosciences, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAnixa Biosciences, Inc. held $15 M more cash than debt (net cash) at Oct 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Anixa Biosciences, Inc.: $97 M ÷ $14 M (31 Jul 2026) = 6.7.
What is Anixa Biosciences, Inc.'s return on equity?
Anixa Biosciences, Inc. lost 73.2% of its shareholders' money over the last year, lower than 62% of Healthcare companies in United States.
How much does Anixa Biosciences, Inc. owe compared with what it owns?
Anixa Biosciences, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Does Anixa Biosciences, Inc. pay a dividend?
No. Anixa Biosciences, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.